131 related articles for article (PubMed ID: 11846327)
1. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
Tsai KS; Yen ML; Pan HA; Wu MH; Cheng WC; Hsu SH; Yen BL; Huang KE
Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
[TBL] [Abstract][Full Text] [Related]
2. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
[TBL] [Abstract][Full Text] [Related]
3. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
5. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
6. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
7. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
8. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
[TBL] [Abstract][Full Text] [Related]
9. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
10. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
[TBL] [Abstract][Full Text] [Related]
11. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
12. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
13. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
[TBL] [Abstract][Full Text] [Related]
14. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Delmas PD; Bjarnason NH; Mitlak BH; Ravoux AC; Shah AS; Huster WJ; Draper M; Christiansen C
N Engl J Med; 1997 Dec; 337(23):1641-7. PubMed ID: 9385122
[TBL] [Abstract][Full Text] [Related]
15. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
17. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
18. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
